FDA Approves Nasal Spray of Teva Opioid Antidote


This is the first generic version of nasal spray that can reverse the effects of opioid overdose that the FDA has approved.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has received FDA approval for Narcan, a life-saving drug that can stop or reverse the effects of an opiate overdose. This is the first nasal spray of generic naloxone hydrochloride that FDA approved.

The deputy director of the FDA's regulatory program center, Douglas Throckmorton, said, "After the opiate crisis, several efforts are being made to make this emergency reversal treatment more readily available and more affordable. In addition to this approval of the first generic naloxone nasal spray, advancing prioritizing our analysis of generic drug applications for naloxone. "

He added, "The FDA has also taken the unprecedented step of helping manufacturers seek approval for an over-the-counter naloxone product and is exploring other ways to increase the availability of naloxone products for community use, including whether Naloxone should be co-prescribed with all or some opioid prescriptions to reduce the risk of death from overdose. "

A package of two Narcan nasal sprays costs about $ 130 to $ 150 without insurance. Teva has not yet said what the generic version will cost.

Posted by Globes, Israel business news – en.globes.co.il – April 21, 2019

© Copyright of Globos Itonut (1983) Ltd. 2019


Picture of Teva: Sivan Faraj

Picture of Teva: Sivan Faraj


Source link